Deutsche Bank AG Invests $40,000 in Oncomed Pharmaceuticals Inc (NASDAQ:OMED)

Deutsche Bank AG acquired a new position in shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 54,700 shares of the biopharmaceutical company’s stock, valued at approximately $40,000. Deutsche Bank AG owned about 0.14% of Oncomed Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of OMED. Acadian Asset Management LLC boosted its holdings in shares of Oncomed Pharmaceuticals by 26.1% in the fourth quarter. Acadian Asset Management LLC now owns 195,107 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 40,353 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Oncomed Pharmaceuticals by 36.1% during the fourth quarter. Geode Capital Management LLC now owns 173,563 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 46,083 shares in the last quarter. Birchview Capital LP grew its holdings in shares of Oncomed Pharmaceuticals by 45.4% during the fourth quarter. Birchview Capital LP now owns 172,557 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 53,868 shares in the last quarter. Norges Bank purchased a new stake in Oncomed Pharmaceuticals in the fourth quarter valued at approximately $136,000. Finally, HarbourVest Partners LLC purchased a new stake in Oncomed Pharmaceuticals in the fourth quarter valued at approximately $1,421,000. 45.16% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research downgraded shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th.

OMED remained flat at $$0.89 during trading on Monday. 1,201 shares of the company’s stock traded hands, compared to its average volume of 768,904. The company has a 50-day moving average of $0.89. Oncomed Pharmaceuticals Inc has a 12 month low of $0.55 and a 12 month high of $3.35. The stock has a market capitalization of $34.43 million, a PE ratio of -5.56 and a beta of 1.86.

About Oncomed Pharmaceuticals

OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer.

Read More: What can cause a stock to outperform?

Institutional Ownership by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.